Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

BACKGROUND: Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60–70% of event-free survival for localized disease at diagnosis. However, for metastatic disease, the prognosis is dismal. Explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cascini, Caterina, Ratti, Chiara, Botti, Laura, Parma, Beatrice, Cancila, Valeria, Salvaggio, Adriana, Meazza, Cristina, Tripodo, Claudio, Colombo, Mario P., Chiodoni, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291774/
https://www.ncbi.nlm.nih.gov/pubmed/37365634
http://dx.doi.org/10.1186/s13046-023-02731-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291774/
https://www.ncbi.nlm.nih.gov/pubmed/37365634
http://dx.doi.org/10.1186/s13046-023-02731-z

Ejemplares similares